Cargando…

OR23-03 Post-Operative Day One Morning Cortisol Value as a Biomarker to Predict the Recurrence of Cushing Disease

Tumor removal by transsphenoidal surgery (TSS) is the first line treatment for Cushing disease (CD). However, recurrence is relatively common. A one week post-operative (post-op) nadir cortisol has been used as a biomarker to predict recurrence(1). We identified 299 CD patients from our longitudinal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fang, Catalino, Michael, Bi, W Linda, Dunn, Ian, Smith, Timothy, Guo, Yunlei, Kaiser, Ursula B, Laws, Edward Raymond, Min, Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207532/ http://dx.doi.org/10.1210/jendso/bvaa046.1046

Ejemplares similares

SAT-LB57 The Spectrum of Genomic and Transcriptomic Alterations in ACTH-Producing and ACTH-Silent Corticotroph Adenomas
por: Lerario, Antonio Marcondes, et al.
Publicado: (2020)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-LB078 Desmopressin Stimulated Salivary Cortisol as a Suplementary Tool in the Diagnosis of Cushing's Syndrome
por: Firme, Ricardo
Publicado: (2019)

SUN-305 Hair Cortisol Measurement: An Innovative Method for Diagnosis and Follow-Up in Patients with Cushing’s Disease
por: Deligiannis, Natalia Gabriela, et al.
Publicado: (2020)

OR23-01 Intrapatient ACTH Variability in Cushing’s Disease: Prognostic Significance
por: Alvarez, Reinier, et al.
Publicado: (2020)

THU031 White Blood Cells (WBC) As Biological Markers Of Cortisol Status In Patients With Cushing's Disease (CD)
por: Mascarenhas-Nakano, Bruna Maria Grosso, et al.
Publicado: (2023)

MON-444 Defining Remission In Cushing Syndrome After Tumor Resection In Cases Of Non-suppressed Postoperative Serum Cortisol Levels
por: McGlotten, Raven, et al.
Publicado: (2019)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

PMON98 High-dose dexamethasone suppression test in ACTH-dependent Cushing's syndrome: Lessons learned on the lack of cortisol suppression
por: Ali, Roshaneh, et al.
Publicado: (2022)

SUN-460 Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
por: Moraitis, Andreas, et al.
Publicado: (2019)

ODP356 The Cortisol Conundrum: The Diagnostic Work up for Patients With Suspected Cushing's Disease and Hypercortisolaemia in Australia. Results of a Survey and Clinical Audit
por: Arulanantham, Jonathan, et al.
Publicado: (2022)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

SAT-256 The Ever Confusing Cushing’s Work Up: Is It Real? Is It Pseudo Cushing’s’? Or Could It Be Factitious
por: Ghalib, Luma, et al.
Publicado: (2020)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

Hypercoagulability in ACTH-Dependent Cushing Syndrome
por: Singh Sumal, Amit Kartar, et al.
Publicado: (2021)

Occult Carcinoid Causes Cushing’s Syndrome
por: Meftali, Sabrina, et al.
Publicado: (2021)

OR20-05 Generation Of CDH23-mutated Pituitary Neuroendocrine Tumor Organoids From Induced Pluripotent Stem Cells To Model Cushing’s Disease Pathogenesis
por: Chakrabarti, Jayati, et al.
Publicado: (2023)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

OR06-01 The Role of Germline Defects in Cushing’s Disease
por: Hernández-Ramírez, Laura C, et al.
Publicado: (2020)

SAT-277 A Fierce Presentation of Cushing Disease
por: Al Sabie, Farah Laith, et al.
Publicado: (2020)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

SAT-LB46 Depression as an Atypical Presentation of Cushing’s Disease
por: Pahwa, Dhivya, et al.
Publicado: (2020)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

USP8 Somatic Mutations in Cushing’s Disease and Silent Corticotropinomas
por: Lamback, Elisa Baranski, et al.
Publicado: (2021)

Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2021)

ODP369 Weight Trajectory as a Predictor of Cushing's Disease
por: Thavaraputta, Subhanudh, et al.
Publicado: (2022)

ODP304 Cyclic Cushing Disease: A Diagnostic Challenge
por: Zubiran, Rafael, et al.
Publicado: (2022)

MON-412 Subclinical Cushing's Disease and the Importance of Broad Differential Diagnoses
por: Walker, Michelle, et al.
Publicado: (2019)

MON-461 Drug Repurposing to Explore Novel Treatment for Cushing Disease
por: Zhang, Dongyun, et al.
Publicado: (2019)

MON-403 Osteoporosis: A Frequently Neglected Consequence of Cushing's Disease
por: Pedro, Jorge, et al.
Publicado: (2019)

SAT-263 A Vicious Cycle of Hypercortisolism - Cyclical Cushing’s Syndrome
por: Force, Bahar Kapoor, et al.
Publicado: (2020)

SAT-266 Accelerated Osteoporosis - a Rare Presentation of Cushing’s Disease
por: Sekar, Vijaykumar, et al.
Publicado: (2020)

SAT-279 Crooke’s Cell Adenoma- an Aggressive Form of Cushing’s Disease
por: Radovanovic, Natasa, et al.
Publicado: (2020)

SAT-300 Evading Death: Noxa in Cushing’s Disease Pituitary Adenomas
por: Alvarez, Reinier, et al.
Publicado: (2020)

SAT-248 Cushing’s Disease with Two ACTH-Producing Pituitary Tumors
por: Mathai, Christine, et al.
Publicado: (2020)

Canine Pituitary Organoids as 3D In Vitro Model for Cushing Disease
por: Sanders, Karin, et al.
Publicado: (2021)

COVID-19 and Cushing Disease: A Protective or a Deadly Combination?
por: Mehfooz, Ayesha, et al.
Publicado: (2021)

PMON149 Identification of TR4 Modulators for Treatment of Cushing Disease.
por: Zhang, Dongyun, et al.
Publicado: (2022)

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE
por: Marin, Luis Madera, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_olecitmfhtq0cf0pm8ladrr9i6